Oncolytics Biotech (ONCY) news
Recent news
OncoLytics Biotech Inc.: H.C. Wainwright cuts target price to $5 from $10
H.C. Wainwright has revised its price target for Oncolytics Biotech Inc. (NASDAQ: ONCY), reducing it from $10 to $5, while maintaining its "Buy" recommendation for the stock. The adjustment reflects updated expectations based on recent developments and market conditions. Despite the lower target,…
AInvest Wire · Aug 19, 2026Oncolytics Biotech gets feedback from FDA over REO 033 design
Oncolytics Biotech has received feedback from the U.S. Food and Drug Administration (FDA) regarding the design of its REO 033 clinical trial, which is evaluating the oncolytic virus pelareorep in combination with checkpoint inhibitors for the treatment of solid tumors. The company has indicated…
AInvest Wire · Aug 18, 2026Oncolytics Biotech - initial REO 33 Part A tumor response update expected by year-end 2026; Part B enrollment may begin Q1 2027
AInvest Wire · Jul 13, 2026Oncolytics Biotech - to hold Type D FDA meeting on REO 33 registration pathway
AInvest Wire · Jul 13, 2026Oncolytics Biotech - remaining REO 33 sites to be activated by end of August for accelerated enrollment in H2 2026
AInvest Wire · Jul 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.